Given the complex neuropathology Alzheimer’s disease (AD), combination therapy may be necessary for effective treatment. However, scientific, pragmatic, regulatory, and business challenges need to be addressed before combination therapy for AD can become a reality. Leaders from academia and industry, along with a former member of the Food and Drug Administration and the Alzheimer’s Association, have explored these challenges and here propose a strategy to facilitate proof-of-concept combination therapy trials in the near future.
from Dementia Big http://ift.tt/1PusyHP
via Stopping Dementia
from WordPress http://ift.tt/1SkMcuy
via alcoholic dementia
http://ift.tt/1pLqFlA
No comments:
Post a Comment